Ann: Suspension from Official Quotation, page-16

Personally just a back to the future share price and market cap of where it was a year ago would be nice. 

That should be the starting point for this board and administration if they improve things from there then I’m converted. I 

I have a question on a Director being paid in shares 

and options just for participating in a Clinical Trial. 

Any reward for this should be based on a successful outcome not a quasi disguised inflated hourly rate with no outcome or measurement. 

The CEO should negotiate the KPI’s that measure and reward a tightly controlled outcome before this even commenced. 

But it is difficult to negotiate with yourself and deliver an outcome that satisfies any basic level

of governance. 

Normally the executive team would sign off & board approval would be sought. 

This appears to be operating at the very edge of any sort of basic governance. 

As a shareholder we should all be asking questions.